吡格列酮可减轻血脂异常的非糖尿病患者的心脏代谢危险因素。

Pioglitazone attenuates cardiometabolic risk factors in non-diabetic patients with dyslipidemia.

作者信息

Hussain Mazhar, Shad Muhammad Nauman, Akhtar Lubna

机构信息

Sheikh Zayed Medical College/Hospital, Rahim Yar Khan.

Islam Dental College, Sialkot, Pakistan.

出版信息

J Pak Med Assoc. 2017 Dec;67(12):1884-1888.

PMID:29256535

Abstract

OBJECTIVE

To determine the effect of pioglitazone on cardiometabolic risk factors in non-diabetic patients with dyslipidaemia.

METHODS

This prospective, randomised clinical trial was conducted at Sheikh Zayed Medical College and Hospital, Rahim Yar Khan, Pakistan, from August to October 2016, and comprised non-diabetic patients with dyslipidaemia. They were randomly divided into three groups. First and second groups were given a daily dose of tab pioglitazone 30mg and gemfibrozil 600mg, respectively, while the third group served as the healthy control. Body weight, body mass index and serum lipid profile were analysed pre- and post-treatment. SPSS 16 was used for data analysis.

RESULTS

Of the 135 participants, there were 45(33.3%) in each group. After 12 weeks' treatment, the pioglitazone group showed a highly significant reduction in body weight (83±10.5 to 76±13.5kg) and body mass index (27.7±4.4 to 25.5±6.4kg/m2) (p<0.01) compared to the gemfibrozil group. The pioglitazone group showed a significant improvement in serum lipid profile after 12 weeks (p<0.05) while the gemfibrozil group showed a highly significant improvement in serum lipid profile (p<0.01).

CONCLUSIONS

Pioglitazone independently improved cardiometabolic risk factors, even in non-diabetics.

摘要

目的

确定吡格列酮对非糖尿病血脂异常患者心血管代谢危险因素的影响。

方法

这项前瞻性随机临床试验于2016年8月至10月在巴基斯坦拉希姆亚尔汗的谢赫扎耶德医学院及医院进行，纳入非糖尿病血脂异常患者。他们被随机分为三组。第一组和第二组分别每日服用30毫克吡格列酮片和600毫克吉非贝齐，而第三组作为健康对照组。在治疗前后分析体重、体重指数和血脂谱。使用SPSS 16进行数据分析。

结果

135名参与者中，每组45人（33.3%）。治疗12周后，与吉非贝齐组相比，吡格列酮组体重（从83±10.5千克降至76±13.5千克）和体重指数（从27.7±4.4千克/平方米降至25.5±6.4千克/平方米）显著降低（p<0.01）。吡格列酮组在12周后血脂谱有显著改善（p<0.05），而吉非贝齐组血脂谱有极显著改善（p<0.01）。